|
The overseas network of Daiwa Pharmaceutical Co., Ltd. has been enhanced.
|
Daiwa Pharmaceutical Co., Ltd. has been building research & development, manufacturing and marketing strategies from a global perspective, and the overseas market has been further expanded.
In most of the major countries in North America, Europe and Asia, the sales of our products through special agents have already been growing. Now, Daiwa Pharmaceutical Co., Ltd. has concluded a sales contract with local leading companies in Russia and Singapore, which has further strengthened the network.
Making inroads into the Russian market is expected to be a breakthrough in entering the former Communist bloc. In addition, Daiwa Pharmaceutical Co., Ltd. will soon start formal negotiations with Arab Middle Eastern countries from which inquiries about the products have been received, as well as South and Central America, China and India.
"BioBran," the main component of "Lentin Plus" (MGN-3), one of our major products, was ranked first in the category of immunostimulation by the US supplement sales ranking for the past two years.
・
Copyright(C)2004 Daiwa Pharmaceutical Co.,Ltd. All rights reserved. | HOME >
|
|
|